Amgen Appoints Madhur Sarin as Director of AI and Data Science Centre of Excellence

Amgen's decision to formalise a dedicated AI and Data Science Centre of Excellence, and appoint a director to lead it, signals a structural shift in how large biopharma organisations are embedding data science into manufacturing quality, regulatory submissions, and enterprise operations. Madhur Sarin takes the role with a mandate to advance scalable AI-driven platforms and strengthen global data science capabilities across healthcare and enterprise technology domains.

For plant heads and QA directors, the operational read is direct: a named COE with dedicated leadership typically precedes deployment of AI tooling into process monitoring, deviation trending, and CAPA workflows. Organisations that have moved from ad hoc analytics to governed, scalable platforms have generally seen measurable reductions in batch release cycle times and improved readiness for data integrity reviews under 21 CFR Part 211 and ICH Q10.

For regulatory affairs leads, the relevance sharpens around submission quality and lifecycle management. AI-assisted authoring, dossier gap analysis, and signal detection are increasingly appearing in agency interactions; a COE structure provides the governance layer that regulators expect when AI outputs inform submission content. Amgen's move aligns with a broader industry pattern in which biopharma companies are institutionalising AI rather than running it as a project-level capability.

Sarin's scope spans both healthcare and enterprise technology domains, suggesting the COE will operate across the full value chain rather than within a single function. That breadth carries implications for data standardisation, model validation protocols, and cross-functional change control, areas where informal AI adoption has historically created compliance exposure.

The measurable outcome to watch is whether Amgen publishes or references its AI governance framework in future regulatory submissions or inspection responses, which would set a visible benchmark for COE-led AI integration across the sector.

Source: Media4Growth via Indian Pharma Post, 25 May 2026.